RecruitingMultiple Myeloma
A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
Eligible age
18+ yrs
Accepts
All genders
Locations
5 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this study is to assess the safety, tolerability and preliminary effectiveness of CC-92480 (BMS-986348) in novel therapeutic combinations for the treatment of Relapsed or Refractory Multiple Myeloma (RRMM).
Sponsor: Bristol-Myers Squibb
You may qualify if…
- ✓ Relapsed or refractory multiple myeloma (MM) and must:
- ✓ 1. Have documented disease progression during or after their last myeloma therapy.
- ✓ 2. For Part 1 Dose Finding: Be refractory to, intolerant to, or not a candidate for available, established therapies known to provide clinical benefit in MM; For Part 2 Dose Expansion: Be refractory to or have relapsed after the protocol specified number of prior lines of therapy that include an immunomodulatory drug (IMiD), a proteasome inhibitor, an anti-CD38 mAb, and a T-cell redirecting therapy (TRT, eg, a CAR-T or T-cell engaging bispecific treatment) unless the participant is not a candidate for TRT.
- ✓ Must have measurable disease.
- ✓ Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1.
- ✓ Agree to follow the CC-92480 Pregnancy Prevention Plan (PPP).
You may not qualify if…
- ✕ Known active or history of central nervous system (CNS) involvement of MM
- ✕ Plasma cell leukemia; Waldenstrom's macroglobulinemia; polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes (POEMS) syndrome; or clinically significant light-chain amyloidosis.
- ✕ Impaired cardiac function or clinically significant cardiac disease
- ✕ Previous SARS-CoV-2 infection within 14 days for asymptomatic or mild symptomatic infections or 28 days for severe/critical illness prior to Cycle 1 Day 1 (C1D1)
- ✕ For Part 1: received prior therapy with CC-92480
- ✕ For Part 2: received prior therapy with CC-92480, tazemetostat, BMS-986158, or trametinib
- ✕ Previously received allogeneic stem-cell transplant at any time or received autologous stem-cell transplant within 12 weeks of initiating study treatment
- ✕ Received any of the following within 14 days prior to initiating study treatment:
Where it's recruiting
Source: ClinicalTrials.gov · NCT05372354 · last updated 2025-09-05